Myriad Genetics' Q3 Revenues up 13 Percent

During a conference call, CEO Peter Meldrum said one important driver for its planned purchase of Rules-based Medicine is the expansion of Myriad's product portfolio beyond oncology and into neuroscience disorders, infectious diseases, and inflammatory diseases.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories